Bayer: Xarelto not working on very sick patients
(CercleFinance.com) - A study on Bayer and Janssen's anticoagulant Xarelto has demonstrated that the drug did not offer additional benefit on top of standard of care in very sick patients, Bayer said on Monday.
Data from a phase III trial evaluationg 5,025 patients from 32 countries showed that, in patients following an acute decompensation of heart failure and concomitant coronary artery disease, there was no statistically significant difference between Xarelto twice daily and placebo, each on top of standard of care, in reducing the composite risk of all-cause mortality, heart attack and stroke.
Another phase III study showed that, compared to placebo, Xarelto did not significantly reduce the composite of symptomatic venous thromboembolism post hospital discharge in high-risk acutely medically ill patients.
Patients at risk of cardiovascular events currently have limited treatment options.
Bayer also announced today that a marketing authorisation application has been submitted to the European Medicines Agency for Larotrectinib in the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Data from a phase III trial evaluationg 5,025 patients from 32 countries showed that, in patients following an acute decompensation of heart failure and concomitant coronary artery disease, there was no statistically significant difference between Xarelto twice daily and placebo, each on top of standard of care, in reducing the composite risk of all-cause mortality, heart attack and stroke.
Another phase III study showed that, compared to placebo, Xarelto did not significantly reduce the composite of symptomatic venous thromboembolism post hospital discharge in high-risk acutely medically ill patients.
Patients at risk of cardiovascular events currently have limited treatment options.
Bayer also announced today that a marketing authorisation application has been submitted to the European Medicines Agency for Larotrectinib in the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Copyright (c) 2018 CercleFinance.com. All rights reserved.